Drugs / Civacir®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00473824 | May 2007 → Feb 2009 | disease related to solid organ transplantation, viral hepatitis | ADMA Biologics, Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01804829 | Jun 2013 → Feb 2016 | cirrhosis of liver, hepatitis C virus infection, hepatocellular carcinoma | Biotest Pharmaceuticals Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Civacir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01804829 ↗ |
| Known as | Hepatitis C Immune Globulin Intravenous (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473824 ↗ |
| Modality | Protein / enzyme biologic | “a polyclonal human hepatitis C immune globulin (Civacir)” NCT00473824 ↗ |
| Route | Intravenous | “18 intravenous infusions over 24 weeks” NCT00473824 ↗ |